In Brief: Bayer/Andrx
This article was originally published in The Tan Sheet
Bayer/Andrx: Enter agreement to develop a new OTC product using Ft. Lauderdale, Fla.-based Andrx' controlled-release drug delivery technologies and a Bayer affiliate's OTC expertise, Andrx announces Sept. 22. Details were not disclosed. Given the move to switch Rx products to OTCs, Andrx considers the arrangement with Bayer the "beginning of an ongoing relationship"...
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC